Clinical trials
Relapsed/Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed/refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 84 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04925609RecruitingPhase 1/Phase 2
Brigatinib for young people with ALK-positive cancer
This trial tests brigatinib, a targeted pill medicine, in children and young adults with ALK-positive cancers (including ALCL and IMT, plus some other solid tumors). It’s designed to see how well it works and what side effects it causes in people whose tumors have a specific ALK change.
ParisAges 1–25 - NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Birmingham, AlabamaAges 12 years+ - NCT07472972Recruiting
Personalized risk tracking for CD19 CAR T therapy
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
Zurich, Canton of ZurichAges Any age - NCT05209620RecruitingPhase 2
Orelabrutinib plus pemetrexed for lymphoma in the brain
This Phase 2 trial tests a combination medicine (orelabrutinib with pemetrexed) to treat lymphoma that has returned or is not responding, specifically in the brain or spinal fluid. If you qualify, the goal is to shrink measurable tumors and improve control of central nervous system lymphoma.
Zhengzhou, HenanAges 18–75 - NCT07574346RecruitingEarly Phase 1
IASO207 injection for relapsed or resistant B-cell lymphoma
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
BeijingAges 18–75 - NCT07450391RecruitingPhase 1/Phase 2
EBV-targeted cell therapy for EBV-related lymph disorders
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
Beijing, Beijing MunicipalityAges 18–70 - NCT06948786RecruitingPhase 2
Pirtobrutinib and Mosunetuzumab for relapsed follicular lymphoma
This trial tests two new drugs, pirtobrutinib and mosunetuzumab, for people with follicular lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help control the cancer.
Seattle, WashingtonAges 18 years+ - NCT01853631RecruitingPhase 1
CAR T-cell therapy for CD19-positive B-cell blood cancers
This Phase 1 study tests a personalized form of immune therapy called CAR T cells that are designed to recognize CD19, a marker on certain B-cell cancers. It may help people with difficult-to-treat (recurrent or relapsed) B-cell lymphoma or leukemia (ALL/CLL).
Houston, TexasAges Up to 75 years - NCT05110742RecruitingPhase 1/Phase 2
CD5-targeting NK cell therapy for blood cancers
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07312630RecruitingEarly Phase 1
A study of LV009 for certain blood cancers
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Hefei, AnhuiAges 18–70 - NCT03765177RecruitingPhase 1/Phase 2
CLIC-1901 for CD19-positive blood and lymphoma cancers
This trial studies a gene-modified cell treatment called CLIC-1901 for people whose CD19-positive cancer has come back or did not respond to prior treatment. It may help shrink the cancer by targeting a protein called CD19 on cancer cells.
Vancouver, British ColumbiaAges 18–75
Hear when a new Relapsed/Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed/refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 84 recruiting relapsed/refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed/refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed/refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed or Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.